findmyKOL
Clinical trialNCT01468207CompletedPhase 3Interventional

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

SponsorAbbVie (prior sponsor, Abbott)Enrollment307Hidradenitis Suppurativa (HS)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2011
Primary completion
31 Jan 2014
Completion
31 Jan 2014
Last update posted
7 Jul 2021
Registered enrollment
307
Registry id
NCT01468207

Cross-registrations

EU-CTR / CTIS (EudraCT)2011-003400-20

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.